

Pharmacy Grand Rounds

200 First Street SW Rochester, Minnesota 55905 https://ce.mayo.edu/pharmacy-grandrounds-2025

Clearing the Air: Comparing Treatments for EGFR-Mutated Non-Small Cell Lung Cancer

Session Date: 09/16/2025

Session Time: 11:00 – 11:45 AM (CST)

Target Audience

This continuing education (CE) session was planned to meet the needs of professional staff who deal with the selection and monitoring of medication(s) as part of their patient care duties, including pharmacists, RNs, APRNs, PAs, MDs.

Activity Overview

Non-small cell lung cancer (NSCLC) remains one of the most common cancers within the United States and the leading cause of cancer-related deaths among men and women. Approximately 15-60% of patients with nonsquamous advanced NSCLCs harbor epidermal growth factor receptor (EGFR) activating mutations, which serve as critical targets for therapy. Tyrosine kinase inhibitors (TKIs), most notably osimertinib, have long been a mainstay for treatment. However, recent data has demonstrated comparable efficacy of amivantamab, an EGFR-MET bispecific antibody, when used in combination with the TKI lazertinib. Current guidelines recommend both osimertinib-based regimens and amivantamab-lazertinib as preferred first-line treatments, yet debate remains regarding the optimal treatment strategy. This presentation aims to explore this debate further by examining current literature comparing the efficacy and safety of these preferred treatment options.

Learning Objectives

At the conclusion of this knowledge-based CE session, participants should be able to:

- 1. Describe the prevalence and common risk factors associated with the development of EGFR-mutated Non-Small Cell Lung Cancer (NSCLC).
- 2. Compare recent literature assessing the safety and efficacy of current preferred first-line treatments for EGFR-mutated metastatic NSCLC.
- 3. Identify toxicities and appropriate supportive care regimens for patients receiving regimens that contain osimertinib, amivantamab, or lazertinib.

Faculty Information

Laura Seitz, PharmD PGY2 Oncology Pharmacy Resident Mayo Clinic Hospital - Rochester, MN

Laura received a Doctor of Pharmacy degree from the University of Wisconsin-Madison School of Pharmacy and is a current PGY2 oncology pharmacy resident at Mayo Clinic Hospital – Rochester. Her practice interests include oncology and hematology.



Approved Provider Statement



In support of improving patient care, this activity is planned and implemented by Mayo Clinic College of Medicine and Science. Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statements

AMA

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE



ACPE Universal Activity Number (UAN): JA0000238-0000-25-035-L01-P Mayo Clinic College of Medicine and Science designates this educational activity for a maximum of 0.75 ACPE Knowledge-based contact hours. Participants should claim only the credit commensurate with the extent of their participation in the activity

ANCC

Mayo Clinic College of Medicine and Science designates this activity for a maximum of 0.75 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

AAPA



Mayo Clinic College of Medicine and Science has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Educational Format and CE Requirements

This CE session is available as a live presentation, including live webcast. Participants must complete the following to record attendance and obtain CE credit:

- 1. Attend the entire session.
- 2. Text the session code to 507-200-3010 within 48 hours of the live presentation to record attendance.
 - a. This number is only used for receiving text messages related to tracking attendance
 - b. Employees are encouraged to create a contact in their mobile phone, as the same number is used to record attendance for every session
- 3. Complete the online evaluation for the respective session within 2 weeks of live presentation.

Pharmacist CE credit is electronically transferred to the National Association of Boards of Pharmacy CPE Monitor. To track CE, please go to NABP CPE Monitor.

Non-pharmacist attendees can print out a record of attendance at ce.mayo.edu after completing the evaluation and claiming credit.

Live Webcast – Register from the Education SharePoint site

Disclosure Summary

As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. All who are in a position to control the content are required to disclose all financial relationships with any ineligible company. Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed:

The faculty report the following relationships:

- Laura Seitz, PharmD
 - O Declares no financial relationship(s) pertinent to this session
 - o Declares off-label use of medications will not be discussed during this presentation

Course Director and Planning Committee Members declare the following relevant financial relationship(s) pertinent to this session.

- No relevant financial relationship(s) with ineligible companies:
 - o Jennifer Elmer, DNP, APRN, CCNS
- Scott Nei, PharmD, BCPS, BCCCP, FCCM, FMSHP

- o Andrew Herber, PA-C
- o Sarah Jane Kotval, BSW, RSS Coordinator

- o Sara Thompson, PharmD, MEd, BCACP
- Relevant financial relationship(s) with ineligible companies:
 - o Wayne Nicholson, MD, PharmD, BCPS Intellectual Property Anivive Lifesciences, Inc.

All relevant financial relationships have been mitigated.

For additional disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee members visit ce.mayo.edu, About Us, Disclosures - or - https://ce.mayo.edu/content/disclosures

System and Technical Requirements

For participants viewing the webcast, sessions are delivered via Mayo Clinic intranet web browser and Adobe® PDF. For participants viewing outside the Mayo Clinic firewall, a VPN connection is required for remote access. Recommended web browser includes Google Chrome. This session is planned and coordinated by **the Department of Pharmacy, Mayo Clinic.**